Cancer Gene Mutations: Why Treatments Fail
- This research, published in Nature Chemical Biology, reveals a key mechanism by which estrogen receptor-positive (ER+) breast cancer cells adapt to stress and become more resistant to therapy.
- Key Revelation: The study identifies a stress-activated control mechanism centered around the Mediator complex, specifically its MED1 subunit.
- * MED1 & Pol II: MED1 works with RNA polymerase II (Pol II) to copy DNA into RNA, driving gene expression.
Summary of the Research on MED1 and Breast Cancer Resistance
This research, published in Nature Chemical Biology, reveals a key mechanism by which estrogen receptor-positive (ER+) breast cancer cells adapt to stress and become more resistant to therapy. Here’s a breakdown of the findings:
Key Revelation: The study identifies a stress-activated control mechanism centered around the Mediator complex, specifically its MED1 subunit. This mechanism allows cancer cells to rapidly reprogram their genetic activity to survive under stressful conditions.
How it Works:
* MED1 & Pol II: MED1 works with RNA polymerase II (Pol II) to copy DNA into RNA, driving gene expression.
* Acetylation & Deacetylation: MED1’s activity is regulated by acetylation (adding an acetyl group) and deacetylation (removing the acetyl group).
* Stress Response: Under stress (hypoxia, oxidative stress, heat), a protein called SIRT1 removes acetyl groups from MED1 (deacetylation).
* Enhanced Gene Activation: Deacetylation allows MED1 to interact more effectively with Pol II, boosting the activation of genes that promote cell survival.
Experimental Evidence:
* Researchers created a mutant version of MED1 that couldn’t be acetylated.
* Cells with this deacetylated MED1 (either naturally through stress or genetically) formed faster-growing and more resistant tumors.
Conclusion:
the switching between acetylation and deacetylation of MED1 acts as a “transcriptional regulatory switch,” enabling cancer cells to quickly adapt and thrive in hostile environments. This pathway is amplified in ER+ breast cancer, contributing to abnormal growth and treatment resistance.
Therapeutic Implications:
This mechanism presents a potential new target for cancer therapy.Interfering with this acetylation/deacetylation process could potentially disrupt the cancer cells’ ability to adapt and survive.